{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T13:23:12Z","timestamp":1772025792378,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T00:00:00Z","timestamp":1547683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T00:00:00Z","timestamp":1547683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Common variable immunodeficiency (CVID) patients have reduced gut microbial diversity compared to healthy controls. The reduced diversity is associated with gut leakage, increased systemic inflammation and ten \u201ckey\u201d bacteria that capture the gut dysbiosis (dysbiosis index) in CVID. Rifaximin is a broad-spectrum non-absorbable antibiotic known to reduce gut leakage (lipopolysaccharides, LPS) in liver disease. In this study, we explored as a \u2018proof of concept\u2019 that altering gut microbial composition could reduce systemic inflammation, using CVID as a disease model. Forty adult CVID patients were randomized, (1:1) to twice-daily oral rifaximin 550\u2009mg versus no treatment for 2 weeks in an open-label, single-centre study. Primary endpoints were reduction in plasma\/serum levels of soluble (s) CD14, sCD25, sCD163, neopterin, CRP, TNF, LPS and selected cytokines measured at 0, 2 and 8 weeks. Secondary endpoint was changes in intra-individual bacterial diversity in stool samples. Rifaximin-use did not significantly change any of the inflammation or gut leakage markers, but decreased gut microbial diversity compared with no treatment (p\u2009=\u20090.002). Importantly, the gut bacteria in the CVID dysbiosis index were not changed by rifaximin. The results suggest that modulating gut microbiota by rifaximin is not the chosen intervention to affect systemic inflammation, at least not in CVID.<\/jats:p>","DOI":"10.1038\/s41598-018-35367-7","type":"journal-article","created":{"date-parts":[[2019,1,12]],"date-time":"2019-01-12T06:58:34Z","timestamp":1547276314000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["RETRACTED ARTICLE: Rifaximin alters gut microbiota profile, but does not affect systemic inflammation - a randomized controlled trial in common variable immunodeficiency"],"prefix":"10.1038","volume":"9","author":[{"given":"S. F.","family":"J\u00f8rgensen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. E.","family":"Macpherson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Bj\u00f8rnetr\u00f8","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Holm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Kummen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Rashidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. E.","family":"Michelsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7962-4726","authenticated-orcid":false,"given":"T.","family":"Lekva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Halvorsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Tr\u00f8seid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. E.","family":"Mollnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. K.","family":"Berge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Yndestad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Ueland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. H.","family":"Karlsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Aukrust","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5900-8096","authenticated-orcid":false,"given":"J. R.","family":"Hov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Fevang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,17]]},"reference":[{"key":"35367_CR1","doi-asserted-by":"publisher","first-page":"pyw020","DOI":"10.1093\/ijnp\/pyw020","volume":"19","author":"P Luczynski","year":"2016","unstructured":"Luczynski, P. et al. Growing up in a Bubble: Using Germ-Free Animals to Assess the Influence of the Gut Microbiota on Brain and Behavior. Int. J. Neuropsychopharmacol.19, pyw020, https:\/\/doi.org\/10.1093\/ijnp\/pyw020 (2016).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"35367_CR2","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nature07540","volume":"457","author":"PJ Turnbaugh","year":"2009","unstructured":"Turnbaugh, P. J. et al. A core gut microbiome in obese and lean twins. Nature457, 480\u2013484, https:\/\/doi.org\/10.1038\/nature07540 (2009).","journal-title":"Nature"},{"key":"35367_CR3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/ismej.2010.92","volume":"5","author":"A Giongo","year":"2011","unstructured":"Giongo, A. et al. Toward defining the autoimmune microbiome for type 1 diabetes. ISME J5, 82\u201391, https:\/\/doi.org\/10.1038\/ismej.2010.92 (2011).","journal-title":"ISME J"},{"key":"35367_CR4","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1161\/Circresaha.116.309219","volume":"119","author":"TN Kelly","year":"2016","unstructured":"Kelly, T. N. et al. Gut Microbiome Associates With Lifetime Cardiovascular Disease Risk Profile Among Bogalusa Heart Study Participants. Circ. Res.119, 956\u2013+, https:\/\/doi.org\/10.1161\/Circresaha.116.309219 (2016).","journal-title":"Circ. Res."},{"key":"35367_CR5","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/mi.2014.107","volume":"8","author":"JF Vazquez-Castellanos","year":"2015","unstructured":"Vazquez-Castellanos, J. F. et al. Altered metabolism of gut microbiota contributes to chronic immune activation in HIV-infected individuals. Mucosal Immunol.8, 760\u2013772, https:\/\/doi.org\/10.1038\/mi.2014.107 (2015).","journal-title":"Mucosal Immunol."},{"issue":"Suppl 1","key":"35367_CR6","doi-asserted-by":"publisher","first-page":"4615","DOI":"10.1073\/pnas.1000082107","volume":"108","author":"YK Lee","year":"2011","unstructured":"Lee, Y. K., Menezes, J. S., Umesaki, Y. & Mazmanian, S. K. Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA108(Suppl 1), 4615\u20134622, https:\/\/doi.org\/10.1073\/pnas.1000082107 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"35367_CR7","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1038\/mi.2016.18","volume":"9","author":"SF Jorgensen","year":"2016","unstructured":"Jorgensen, S. F. et al. Altered gut microbiota profile in common variable immunodeficiency associates with levels of lipopolysaccharide and markers of systemic immune activation. Mucosal Immunol.9, 1455\u20131465, https:\/\/doi.org\/10.1038\/mi.2016.18 (2016).","journal-title":"Mucosal Immunol."},{"key":"35367_CR8","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1586\/eci.09.43","volume":"5","author":"S Ahn","year":"2009","unstructured":"Ahn, S. & Cunningham-Rundles, C. Role of B cells in common variable immune deficiency. Expert Rev. Clin. Immunol.5, 557\u2013564, https:\/\/doi.org\/10.1586\/eci.09.43 (2009).","journal-title":"Expert Rev. Clin. Immunol."},{"key":"35367_CR9","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1182\/blood-2007-11-124545","volume":"112","author":"H Chapel","year":"2008","unstructured":"Chapel, H. et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood112, 277\u2013286, https:\/\/doi.org\/10.1182\/blood-2007-11-124545 (2008).","journal-title":"Blood"},{"key":"35367_CR10","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/ajg.2016.329","volume":"111","author":"SF Jorgensen","year":"2016","unstructured":"Jorgensen, S. F. et al. A Cross-Sectional Study of the Prevalence of Gastrointestinal Symptoms and Pathology in Patients With Common Variable Immunodeficiency. Am. J. Gastroenterol.111, 1467\u20131475, https:\/\/doi.org\/10.1038\/ajg.2016.329 (2016).","journal-title":"Am. J. Gastroenterol."},{"key":"35367_CR11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/B978-0-12-385991-4.00002-7","volume":"111","author":"PF Yong","year":"2011","unstructured":"Yong, P. F., Thaventhiran, J. E. & Grimbacher, B. \u201cA rose is a rose is a rose,\u201d but CVID is Not CVID common variable immune deficiency (CVID), what do we know in 2011? Adv. Immunol.111, 47\u2013107, https:\/\/doi.org\/10.1016\/B978-0-12-385991-4.00002-7 (2011).","journal-title":"Adv. Immunol."},{"key":"35367_CR12","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/ni.1863","volume":"11","author":"T Kawai","year":"2010","unstructured":"Kawai, T. & Akira, S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol.11, 373\u2013384, https:\/\/doi.org\/10.1038\/ni.1863 (2010).","journal-title":"Nat. Immunol."},{"key":"35367_CR13","doi-asserted-by":"publisher","first-page":"e60042","DOI":"10.1371\/journal.pone.0060042","volume":"8","author":"JS Bajaj","year":"2013","unstructured":"Bajaj, J. S. et al. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One8, e60042, https:\/\/doi.org\/10.1371\/journal.pone.0060042 (2013).","journal-title":"PLoS One"},{"key":"35367_CR14","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/ja.2014.106","volume":"67","author":"F Calanni","year":"2014","unstructured":"Calanni, F., Renzulli, C., Barbanti, M. & Viscomi, G. C. Rifaximin: beyond the traditional antibiotic activity. J. Antibiot. (Tokyo)67, 667\u2013670, https:\/\/doi.org\/10.1038\/ja.2014.106 (2014).","journal-title":"J. Antibiot. (Tokyo)"},{"key":"35367_CR15","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1097\/MPH.0b013e31827e56af","volume":"35","author":"M Qayed","year":"2013","unstructured":"Qayed, M. et al. Rifaximin for preventing acute graft-versus-host disease: impact on plasma markers of inflammation and T-cell activation. J. Pediatr. Hematol. Oncol.35, e149\u2013152, https:\/\/doi.org\/10.1097\/MPH.0b013e31827e56af (2013).","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"35367_CR16","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1093\/infdis\/jiu515","volume":"211","author":"AR Tenorio","year":"2015","unstructured":"Tenorio, A. R. et al. Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286. J. Infect. Dis.211, 780\u2013790, https:\/\/doi.org\/10.1093\/infdis\/jiu515 (2015).","journal-title":"J. Infect. Dis."},{"key":"35367_CR17","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","volume":"362","author":"NM Bass","year":"2010","unstructured":"Bass, N. M. et al. Rifaximin treatment in hepatic encephalopathy. N. Engl. J. Med.362, 1071\u20131081, https:\/\/doi.org\/10.1056\/NEJMoa0907893 (2010).","journal-title":"N. Engl. J. Med."},{"key":"35367_CR18","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/j.1478-3231.2011.02650.x","volume":"32","author":"GN Kalambokis","year":"2012","unstructured":"Kalambokis, G. N., Mouzaki, A., Rodi, M. & Tsianos, E. V. Rifaximin improves thrombocytopenia in patients with alcoholic cirrhosis in association with reduction of endotoxaemia. Liver Int32, 467\u2013475, https:\/\/doi.org\/10.1111\/j.1478-3231.2011.02650.x (2012).","journal-title":"Liver Int"},{"key":"35367_CR19","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1097\/meg.0000000000000348","volume":"27","author":"V Gangarapu","year":"2015","unstructured":"Gangarapu, V. et al. Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease. Eur. J. Gastroenterol. Hepatol.27, 840\u2013845, https:\/\/doi.org\/10.1097\/meg.0000000000000348 (2015).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"35367_CR20","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/1751-2980.12294","volume":"16","author":"X Zeng","year":"2015","unstructured":"Zeng, X. et al. Does low-dose rifaximin ameliorate endotoxemia in patients with liver cirrhosis: a prospective study. J. Dig. Dis.16, 665\u2013674, https:\/\/doi.org\/10.1111\/1751-2980.12294 (2015).","journal-title":"J. Dig. Dis."},{"key":"35367_CR21","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.jhep.2013.01.003","volume":"58","author":"G Kakiyama","year":"2013","unstructured":"Kakiyama, G. et al. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J. Hepatol.58, 949\u2013955, https:\/\/doi.org\/10.1016\/j.jhep.2013.01.003 (2013).","journal-title":"J. Hepatol."},{"key":"35367_CR22","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1093\/ecco-jcc\/jjv204","volume":"10","author":"D Kevans","year":"2016","unstructured":"Kevans, D. et al. Characterization of Intestinal Microbiota in Ulcerative Colitis Patients with and without Primary Sclerosing Cholangitis. J Crohns Colitis10, 330\u2013337, https:\/\/doi.org\/10.1093\/ecco-jcc\/jjv204 (2016).","journal-title":"J Crohns Colitis"},{"key":"35367_CR23","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1136\/gut.2008.165886","volume":"58","author":"PD Cani","year":"2009","unstructured":"Cani, P. D. et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut58, 1091\u20131103, https:\/\/doi.org\/10.1136\/gut.2008.165886 (2009).","journal-title":"Gut"},{"issue":"Suppl 1","key":"35367_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1046\/j.1365-2249.1999.00109.x","volume":"118","author":"Primary immunodeficiency diseases","year":"1999","unstructured":"Primary immunodeficiency diseases. Report of an IUIS Scientific Committee. International Union of Immunological Societies. Clin. Exp. Immunol.118(Suppl 1), 1\u201328, https:\/\/doi.org\/10.1046\/j.1365-2249.1999.00109.x (1999).","journal-title":"Clin. Exp. Immunol."},{"key":"35367_CR25","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3389\/fimmu.2014.00162","volume":"5","author":"W Al-Herz","year":"2014","unstructured":"Al-Herz, W. et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front. Immunol.5, 162, https:\/\/doi.org\/10.3389\/fimmu.2014.00162 (2014).","journal-title":"Front. Immunol."},{"key":"35367_CR26","doi-asserted-by":"publisher","first-page":"609","DOI":"10.7326\/0003-4819-108-4-609","volume":"108","author":"DA Ahlquist","year":"1988","unstructured":"Ahlquist, D. A., Schwartz, S., Isaacson, J. & Ellefson, M. A stool collection device: the first step in occult blood testing. Ann. Intern. Med.108, 609\u2013612 (1988).","journal-title":"Ann. Intern. Med."},{"key":"35367_CR27","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/1471-2180-10-206","volume":"10","author":"GD Wu","year":"2010","unstructured":"Wu, G. D. et al. Sampling and pyrosequencing methods for characterizing bacterial communities in the human gut using 16S sequence tags. BMC Microbiol.10, 206, https:\/\/doi.org\/10.1186\/1471-2180-10-206 (2010).","journal-title":"BMC Microbiol."},{"key":"35367_CR28","doi-asserted-by":"publisher","first-page":"5112","DOI":"10.1128\/aem.01043-13","volume":"79","author":"JJ Kozich","year":"2013","unstructured":"Kozich, J. J., Westcott, S. L., Baxter, N. T., Highlander, S. K. & Schloss, P. D. Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the MiSeq Illumina sequencing platform. Appl. Environ. Microbiol.79, 5112\u20135120, https:\/\/doi.org\/10.1128\/aem.01043-13 (2013).","journal-title":"Appl. Environ. Microbiol."}],"updated-by":[{"DOI":"10.1038\/s41598-024-54117-6","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:00:00Z","timestamp":1707868800000},"record-id":"51891"},{"DOI":"10.1038\/s41598-024-54117-6","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:00:00Z","timestamp":1707868800000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-35367-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-35367-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-35367-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T07:11:12Z","timestamp":1708413072000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-35367-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,17]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["35367"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-35367-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,17]]},"assertion":[{"value":"10 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been retracted. Please see the Retraction Notice for more detail:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-024-54117-6","URL":"https:\/\/doi.org\/10.1038\/s41598-024-54117-6","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"167"}}